This is the public evidence browser: searchable references, visible evidence tiers, and enough filtering to stop this page from feeling like a dump.
Use search plus tier, year, and study type filters. Visible counts update live and the URL keeps your filter state.
Showing 16 references.
Key claim: Higher and better-quality skeletal muscle mass (NAMA) was associated with lower all-cause mortality and lower ESKD risk in ADPKD
Limitations: Observational design with potential residual confounding; muscle strength/performance not captured; single-country tertiary-center cohort
Open sourceKey claim: Ketogenic-style interventions show metabolic feasibility but renal structural disease-modifying evidence remains uncertain
Limitations: Small heterogeneous short-duration studies; no robust pooled effect on hard renal outcomes
Open sourceKey claim: Tolvaptan group showed slower htTKV growth and better 2-year eGFR trajectory vs untreated controls in this cohort
Limitations: Small non-randomized sample and potential selection bias; country/cohort-specific
Open sourceKey claim: Pravastatin did not reduce annual htTKV growth or slow kidney blood-flow/kidney-function decline versus placebo over 2 years in adults with preserved kidney function
Limitations: Single pharmacologic class/intervention; findings apply to pravastatin regimen tested and do not exclude other pathways
Open sourceKey claim: DCE-MRI intrarenal Ktrans was reproducible with phantom correction, distinguished mild vs severe ADPKD, and correlated with htTKV and eGFR, supporting perfusion biomarker feasibility
Limitations: Small single-center cohort and short repeat-interval imaging design; biomarker validation does not establish treatment efficacy or hard-outcome benefit
Open sourceKey claim: Lower baseline renal blood flow independently associated with higher long-term risk of kidney failure and faster progression metrics in early-stage ADPKD
Limitations: Observational/prognostic design and MRI-based RBF measurement may limit generalizability and interventional inference
Open sourceKey claim: Association with modest chronic eGFR slope benefit estimate but not statistically significant; high discontinuation rates
Limitations: Observational design with residual confounding and wide confidence intervals; tertiary-centre cohort
Open sourceKey claim: Supports structured management of extrarenal manifestations and highlights implementation/research gaps
Limitations: Commentary not primary efficacy trial; focus on implementation and hepatopancreatic scope
Open sourceKey claim: Risk-stratified management and evidence-based treatment framework
Limitations: Needs full-text extraction for recommendation-level detail
Open sourceKey claim: Provides full recommendation set for evaluation/risk stratification and treatment of ADPKD
Limitations: No abstract-level efficacy quantification in PubMed listing; full-text extraction needed for recommendation granularity
Open sourceKey claim: In tolvaptan-treated ADPKD, 6-month dapagliflozin add-on was associated with attenuated eGFR slope decline and lower TKV growth versus control period
Limitations: Small single-country open-label crossover and short follow-up; surrogate endpoints; needs larger blinded confirmation
Open sourceKey claim: Tolvaptan has clinically relevant liver-injury risk requiring monitoring
Limitations: Generalizability outside trial settings
Open sourceKey claim: CRISPR-based mechanistic editing reduced disease severity in models
Limitations: Preclinical only; no human efficacy
Open sourceKey claim: Prescribed high water intake reduced urine osmolality but did not slow htTKV growth versus ad libitum intake over 3 years
Limitations: Only about half achieved urine-osmolality adherence target and no long-term copeptin reduction was seen; not a no-hydration trial
Open sourceKey claim: Slower eGFR decline than placebo over 1 year
Limitations: Monitoring and tolerability constraints remain
Open sourceKey claim: Slowed TKV growth and kidney function decline vs placebo over 3 years
Limitations: Adverse effects/discontinuation burden; selected population
Open sourceTry clearing one filter, broadening the search term, or switching back to higher-level evidence tiers first.